BioSight
Companies
Innoviva, Inc. logo

INVA

NASDAQBURLINGAME, CA
Innoviva, Inc.

Innoviva receives royalty payments from respiratory products commercialized by GSK, including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, and holds royalty interests in other marketed drugs across multiple therapeutic areas such as infectious disease and critical care. The company's revenue model is dependent on the continued commercial performance and market adoption of these partnered products rather than on developing its own pipeline of drug candidates.

Price history not yet available for INVA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar